Stay updated with breaking news from Second Closing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the...
LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the...
Press release content from Accesswire. The AP news staff was not involved in its creation. Envirotech Vehicles Completes Second Closing of Private Placement May 10, 2021 GMT This is the Second Closing of a Previously Announced $23 Million Private PlacementCORONA, CA / ACCESSWIRE / May 10, 2021 / ADOMANI, Inc. (OTCQB:ADOM) (DBA Envirotech Vehicles) a provider of new zero-emission, purpose-built electric vehicles and ... This is the Second Closing of a Previously Announced $23 Million Private PlacementCORONA, CA / ACCESSWIRE / May 10, 2021 / ADOMANI, Inc. (OTCQB:ADOM) (DBA Envirotech Vehicles) ...
4Bio Capital 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round Press Release 1 March 2021 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced it has become an investor in CARISMA Therapeutics, a biopharmaceutical company focused on discovering and developing innovative immunotherapies. 4BIO participated in the second...